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Abstract
Background: Accumulating evidence has shown that different immunotherapies for ovarian cancer might overcome
barriers to resistance to standard chemotherapy. The vaccine immunotherapy may be a useful one addition to
conditional chemotherapy regimens. The present study investigated the use of vaccine of ovarian cancer stem cells
(CSCs) to inhibit ovarian cancer growth.
Methods: CD117+CD44+CSCs were isolated from human epithelial ovarian cancer (EOC) SKOV3 cell line by using a
magnetic-activated cell sorting system. Pre-inactivated CD117+CD44+CSC vaccine was vacccinated into athymic nude
mice three times, and then the mice were challenged subcutaneously with SKOV3 cells. The anti-tumor efficacy of CSC
vaccine was envaluated by in vivo tumorigenicity, immune efficient analysis by flow cytometer, and enzyme-linked
immunosorbent assays, respectively.
Results: The CD117+ CD44+CSC vaccine increased anti-ovarian cancer efficacy in that it depressed ovarian cancer growth
in the athymic nude mice. Vaccination resulted in enhanced serum IFN-γ, decreased TGF-β levels, and increased cytotoxic
activity of natural killer cells in the CD117+ CD44+CSC vaccine immunized mice. Moreover, the CSC-based vaccine
significantly reduced the CD117+CD44+CSC as well as the aldehyde dehydrogenase 1 positive cell populations in the
ovarian cancer tissues in the xenograft mice.
Conclusion: The present study provided the first evidence that human SKOV3 CD117+ CD44+CSC-based vaccine may
induce the anti-ovarian cancer immunity against tumor growth by reducing the CD117+CD44+CSC population.
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Background
Epithelial ovarian cancer (EOC) is the leading cause of
death from gynecologic malignancy in the China. Most
asymptomatic early stage patients are lack of early diagnos-
tic tools, thus the disease is usually diagnosed in a late stage.
Despite ovarian cancer a highly chemosensitive disease, it is
only infrequently cured. One of the main reasons lies in the
presence of drug-resistant cancer stem cells (CSCs) that
represent a subset of cells in the bulk of tumors and play a
key role in the onset of tumor recurrence, distant metasta-
sis, and drug-resistance [1, 2]. In EOC, CD117+CD44+cell
phenotypes express CSC markers, and can survive conven-
tional therapies such as chemotherapy, and give rise to
recurrent tumors that are more chemo-resistant and more
aggressive [2, 3]. Thus, novel approaches to CSC therapy
are needed urgently to address this clinical need.
Accumulating evidence has suggested that the immune
system has its ability to recognize and eliminate micro-
scopic disease, and it may be paramount in preventing
tumor recurrence. Ovarian cancer vaccines that target tu-
mors through inducing immune responses against tumor
cells, are a promising novel immunotherapy strategy
addition to the treatment of ovarian cancer. However, ovar-
ian cancer-specific vaccines have demonstrated minimal
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clinical efficacy in patients with established drug-resistant
and metastasis disease [4, 5]. Emerging study suggests that
the addition of immunotherapy to existing therapeutic
options could lead to a great improvement in the outcome
of ovarian cancer immune tolerance, especially when tar-
geting CSCs [6]. Thus, vaccination directed at CSCs may
broaden the antigenic breadth and function as a tumor-
associated antigen, and stimulate the immune responses
against autologous ovarian cancer cells [7, 8]. Towards this
end, we used the previously identified EOC CSCs that have
the CD117+CD44+cell phenotypes in human EOC SKOV3
cell line [2, 3, 9, 10] to investigate the therapeutic potential
of this vaccine for targeting EOC CSCs in the study.
Here we showed that the SKOV3 CD117+CD44+CSC
vaccine elicited strongly anti-ovarian cancer immune
responses that significantly led to suppressing tumor
growth, decreasing CD117+CD44+CSC and aldehyde de-
hydrogenase 1 (ALDH1) positive cell populations in tumor
tissues in the vaccinated nude mice. This CSC vaccine pro-
vided a potential anti-ovarian cancer regimen for inhibiting
EOC CSC’s growth in mice.
Materials and methods
Cell lines and mice
Human EOC SKOV3 cell line was acquired from an ovarian
cancer patient, which is a well-established ovarian cancer
model system; YAC-1 cell line is Moloney leukemia-
induced T-cell lymphoma of A/Sn mouse origin. These cell
lines were purchased from the Cellular Institute in Shang-
hai, China. Cells were cultured in complete media consisting
of RPMI 1640, 2 mM L-glutamine, 100 U/ml penicillin,
100 μg/ml streptomycin, and 10 % fetal bovine serum (FBS).
The medium was refreshed every 3 days to maintain
adherent cells. When SKOV3 cells reached 90 % conflu-
ence, cells were harvested with 0.25 % trypsin-1 mM EDTA
(Sigma- Aldrich, St. Louis, MO, USA) treatment for 2 mins.
YAC-1 cells were conditional cultured and passaged in
RPMI 1640 medium.
Balb/c athymic nude mice of 5–6 weeks of age were
acquired from the Animal Center of Yang Zhou University
of China (license number: SCXK, Jiangsu province of
China, 2007–0001) and were raised under sterile conditions
in air-filtered containers at the Experimental Animal
Center, School of Medicine, Southeast University. All the
experiments were performed in compliance with the guide-
lines of the Animal Research Ethics Board of Southeast
University, China. Full details of approval of the study can
be found in the approval ID: 20080925.
Isolation of CD44+CD117+cells
CD44+CD117+cells were isolated from the SKOV-3 cell line
using the magnetic-activated cell sorting (MACS) method
that was performed as described previously [10, 11]. Briefly,
CD44+subsets were first isolated using the mouse
antihuman CD44 antibody coupled to magnetic microbe-
ads (code number: 130-095-194, antibody dilution, 1:20,
Miltenyi Biotec., Bergisch Gladbach, Germany) and
followed by the magnetic column selection or depletion.
The resulting cells were then depleted of CD117 negative
subsets using mouse antihuman CD117 antibody
coupled to magnetic microbeads (code number: 130-
091-332, antibody dilution, 1:20, Miltenyi Biotec.,
Bergisch Gladbach, Germany). The CD44+CD117+cells
were named for the EOC cancer stem cells as ‘EOC
SKOV-3 CD44+CD117+CSCs’, and the resulting cells
were named for the EOC non-cancer stem cells as
‘EOC SKOV-3 non-CD44+ CD117+ CSCs’ [3, 10–12].
The isolated cells were placed in stem cell culture
medium by resuspension in serum-free DMEM/F12
supplemented with 20 ng/mL human recombinant epider-
mal growth factor (Invitrogen, CA, USA), 10 ng/mL
basic fibroblast growth factor (Invitrogen, CA, USA),
5 μg/mL insulin (Sigma-Aldrich, Missouri, USA), and
0.5 % bovine serum albumin (Sigma- Aldrich, Missouri,
USA) [13, 14]. The isolated CD44+CD117+CSCs were
further identified by using a flow cytometer (FCM,
BD, USA) [15].
Mouse immunization protocol
Balb/c nude mice were used to assess the in vivo CSC vac-
cine efficacy. Twelve mice (female, weight: 16–18 g and
age between 5 and 6 weeks) were randomly divided into
four groups of equal size (three per group): the SKOV3
CD117+CD44+CSC group, the SKOV3 non-CD117+
CD44+CSC group, the SKOV3 cell group, and the
phosphate-buffered saline (PBS) group. The nude mice re-
ceived subcutaneous vaccination in the right flank with
mitomycin C (50 μg/ml) inactivated above different vac-
cines (5 × 104) three times, an interval of 14 days between
the immunizations. All immunized mice were challenged
subcutaneously with 5 × 106 SKOV3 cells 10 days after
final vaccination. Tumor formations in each mouse was
monitored every 3-5 days by taking 2-dimensional mea-
surements of individual tumors, and then the tumor-free
mice were observed, respectively [16]. Mice were also
monitored for the general health indicators such as overall
behavior, feeding, body weight and appearance of fur after
vaccination. The endpoint for this study was one
diameter of tumor ≥20 mm, at which point mice were
euthanized. Vaccine immunization and in vivo
tumorigenicity experiment was repeated twice.
Enzyme-linked immunosorbent assay (ELISA)
Fresh blood from all mouse groups was obtained before
sacrificing by anesthesia. Serum levels of interferon-γ
(IFN-γ) and transforming growth factor-β (TGF-β) was
measured using a commercially available ELISA kits ac-
cording to the manufacturer’s protocol (eBioscience, San
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Jose, CA, USA). Briefly, the serum samples were diluted
at 1:10, and each cytokine was captured by the specific
primary antibody and detected by biotin-labeled second-
ary antibody. Plate was read at 450/570 nm using a mi-
croplate reader (Bio-Rad Labs, Hercules, CA, USA).
Samples and standards were run in triplicate, and the
sensitivity of the assay was 0.1 units/ml for IFN-γ and
TGF-β. The Kit is suitable for detecting samples that in-
clude cell culture supernatant and serum [17, 18].
NK cytotoxicity
At the end of the experiments, the spleen tissues were
harvested from the immunized mice. 5 × 106 splenocytes
were labeled with 0.5 mM 5-(and 6)-carboxy-fluorescein
diacetate succinimidyl ester (CFSE; 20 μg/ml) at 37 °C
for 20 mins. Splenocytes were washed twice in PBS con-
taining 5 % FBS to sequester any free CFSE. The CFSE-
labeled splenocytes as effector cells were seeded with a
constant number of YAC-1 target cells in a 96-well plate
at 25:1 ratios of effector cells to target cells. Flow cyto-
metric CFSE/7-AAD cytotoxicity assay was analyzed by
FCM [19, 20].
Quantitative real-time reverse transcription-PCR (qRT-PCR)
qRT-PCR analysis was performed on an ABI step one
plus real-time system (Applied Biosystems). Total cellu-
lar RNA was isolated from each sample by using a Qia-
gen RNeasy Kit (Qiagen, Valencia, CA). One microgram
of total RNA from each sample was subjected to cDNA
synthesis using the Superscript III reverse transcriptase
(Invitrogen). cDNAs were amplified by PCR with
primers as follows: Perforin (sense, 5′-TCCTATGGCA
CGCACTT TATCAC-3′; antisense, 5′-TCCACGTTCA
GGCAGTCTCCTAC-3′); Granzyme B (sense, 5′-GCTG
CTAAAGCTGAAGAGTAAGG-3′; antisense, 5′-GCG
TGTTTGAGTATTTGCCC A TT-3′); TGF-β (sense, 5'-
TGGAAACCCACAACGAAATCT-3′; antisense, 5'-GCT
GAGGT ATCGCCAGGAAT-3′); β-actin (sense, 5′-TTT
CCAGCCTTCCTT CTTGGGTAT-3′; antisense, 5′-
TGTTGG CATAGAGGTCTTTACGG-3′). The mRNA
levels of the genes of interest were expressed as the ratio
of each gene of interest to β-actin for each sample. SYBR
Green quantitative PCR amplifications was performed in
the Step one plus Detection System (Applied Biosys-
tems). The comparative Ct (ΔΔCt) method was used to
determine the expression fold change [3].
Analysis of CD44+CD117+CSC population in tumor tissues
The ovarian cancer tissues were harvested from the mice
immunized with the different vaccines at the end of the
experiments, and were developed into cell suspension
that were used to analyze the CD44+CD117+CSC popu-
lation by FCM assay. Briefly, a total of 2 × 105 tumor
cells were suspended in PBS and labeled with anti-
Human/Mouse CD44 fluorescein isothiocyanate (FITC)
1:100 (eBioscience, CA, USA), and anti-Human CD117
phycoerythrin (PE) 1:20 (eBioscience, CA, USA) anti-
bodies for immunofluorescence detection. Equal number
of the cells cultured in stem cell culture medium was an-
alyzed by FCM with Beckman Coulter Cell Quest soft-
ware [9, 21].
Analysis of ALDH1 activity in cells
Analysis of ALDH1 activity in cells was performed using
a commercially ALDEFLUOR kit (StemCell Technolo-
gies, Durham, NC, USA) according to the manufac-
turer’s protocol as described in the published papers
[1, 22]. Briefly, cells obtained from freshly dissociated
ovarian cancer tissues from the mice immunized with
the different vaccines were suspended in ALDEFLUOR
assay buffer containing ALDH substrate (BAAA,
1 μmol/l per 1 × 106 cells) and incubated during 45 mins
at 37 °C. As negative control, each sample of cells an ali-
quot was treated with 50 mmol/l diethylaminobenzalde-
hyde (DEAB), a specific ALDH inhibitor. To clear cells
of mouse origin from the xenotransplanted tumors, we
used staining with an anti-H2Kd antibody (BD biosci-
ences, 1/200, 30 min on ice) followed by staining with a
secondary antibody labeled with PE (Jackson labs, 1/250,
30 min on ice). The sorting gates were established using
as negative controls. For viability, the ALDEFLUOR-
stained cells treated with DEAB and the staining with
secondary antibody alone. Analysis was performed by
using a FCM (BD, USA) [9, 19].
Statistical analysis
Values of interest were presented as the average of ±
S.D. for at least three independent experiments. Dif-
ferences between the test and the control conditions
were assessed by Student’s t test analysis. Bonferroni
correction was used where multiple comparisons
were made. Statistically significant difference is indi-
cated by: * when p < 0.05, ** when p < 0.01 and ***
when p < 0.003.
Results
SKOV3 CD117+CD44+CSC vaccine inhibits the ovarian
cancer growth in the vaccinated nude mice
In this study, we first wanted to know whether the
SKOV3 CD117+CD44+CSC vaccine would elicit an im-
mune response against SKOV3 ovarian cancer in nude
mouse model. Figure 1a shows that images of tumor
sizes on day 47 after the immunized mice were chal-
lenged with SKOV3 cells. It was found that the all mice
immunized with the CD117+CD44+CSC vaccine grew
tumors in 22 days but the tumor volume was statistically
significant decreased compared with the mice immu-
nized with the SKOV3 cell vaccine (*p < 0.05) or the
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non-CD117+ CD44+CSC vaccine (**p < 0.01). The time
of tumor occurrence in the CD117+CD44+CSC vac-
cined mice was also markedly postponed in contrast
to the mice immunized with the non-CD117+CD44
+CSC and the SKOV3 cell vaccines (*p < 0.05), which
are shown in Fig. 1b and c. Whereas the tumor sizes
from the mice immunized with PBS (Fig. 1a) were
bigger than that of mice immunized with the CD117
+CD44+CSC (***p < 0.003); the time of tumor occur-
rence was also earlyer than that of mice immunized
with the other vaccines (*p < 0.05). From these results,
we concluded that the SKOV3 ovarian cancer growth
was significantly inhibited in the mice vaccinated with
the SKOV3 CD117+CD44+CSC-based vaccine.
SKOV3 CD117+CD44+CSC vaccine elicits a strong immune
responses in vaccinated nude mice
To evaluate the immune efficacy of the SKOV3 CD117
+CD44+CSC-based vaccine, we tested the levels of IFN-γ
and TGF-β. Figure 2a shows the serum IFN-γ level was
significantly increased in the CD117+CD44+CSC vaccine
group compared with the non-CD117+CD44+CSC vac-
cine group (*p < 0.05) or SKOV3 cell vaccine group
(*p < 0.05) or PBS group (**p < 0.01). Whereas the
TGF-β level was significantly decreased in the CD117
+CD44+CSC vaccine group in contrast to the SKOV3 cell
vaccine (*p < 0.05) and non-CD117+CD44+CSC groups
(**p < 0.01), and PBS group (***p < 0.003), respectively, as
is shown in Fig. 2b. Similarly, the tumor tissue TGF-β level
Fig. 1 CD117+CD44+CSC vaccine exhibits a potent antitumor activity in mouse ovarian cancer model. a Images exhibits the tumor sizes dissected
from the vaccineated mice 47 days after mice were challenged with SKOV3 cells. The nude mice received subcutaneous vaccination in the right flank
with 50 μg/ml mitomycin C inactivated 5 × 105 different cell vaccines respectively. A vaccination cycle is consisted of three vaccinations at a biweekly
interval. Alive SKOV3 cells (5 × 105) were injected subcutaneously in the left flank 10 days after the final vaccination; b The dynamic state changes of
tumor volumes in SKOV3 ovarian cancer beraing nude mice; c Tumor free nude mice challenged with SKOV3 cells
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was markedly reduced in the CD117+CD44+CSC vaccine
group in contrast to the control groups as is shown in
Fig. 2c. These consistent cytokine level changes may be a
helpful for eliciting the immune responses against SKOV3
ovarian cancer in nude mice.
Comparison of the cytotoxicity of NK cells between the
different vaccines immunized mice
Since the cytotoxic activity of immune cells following
administration of xenogeneic cancer vaccine in mice
may represent an antitumor immunity efficacy, we there-
fore analyzed the NK cytotoxicity in the vaccinated mice
in four separated experiments. Figure 3a gives the NK
cytotoxicity (splenocytes against target cells YAC-1) in
the SKOV3 CD117+CD44+CSC vaccine group was the
highest (49.9 %) among 4 group vaccines, and the
SKOV3 non-CD117+ CD44+CSC vaccine group ranked
second (33.5 %). The NK cytotoxic activity was the low-
est in the PBS group (26.7 %). There were a significant
differences between the SKOV3 CD117+ CD44+CSC and
SKOV3 vaccine groups (*p < 0.05), between the
SKOV3 CD117+CD44+CSC and the SKOV3 non-
CD117+ CD44+CSC vaccine groups (**p < 0.01), and
between the SKOV3 CD117+CD44+CSC vaccine and
PBS groups (**p < 0.01) as is shown in Fig. 3b.
NK cell performance of the cytotoxicity against target
cells mainly depends on releasing effective molecules,
perforin and granzyme B, so we further tested the ex-
pression of the two molecules in ovarian cancer tissues.
Consistently, the expression of perforin and granzyme
was significantly increasd in the SKOV3 CD117+CD44
+CSC vaccine group compared with other control
groups, which was statistically significant (Fig. 3c and d).
Analysis of the CD44+CD117+cell as well as ALDH-positive
cell populations in vaccinated mice challenged with
SKOV3 cells
To assess the targeted effect of the CSC vaccine on elim-
ination of CD44+CD117+CSCs, we investigated the
CD44+CD117+double positive cell population in ovarian
cancer tissues from the vaccinated mice. Figure 4a gives
that in the PBS immunized mice, CD44+CD117+double
positive cells were accounting for 12.7 % that was the
highest among 4 groups, which was statistically signifi-
cant compared with the SKOV3 CD44+CD117+CSC vac-
cine group (1.55 %, ***p <0.003); whereas the CD44
+CD117+CSC vaccine group and the non-CD44+ CD117
+CSC vaccine group had different CD44+CD117+cell
population rates(1.55 % in the CSC vaccine group vs
2.43 % in the SKOV3 cell vaccine group; see Fig. 4a).
Fig. 2 Levels of IFN-γ and TGF-β in the vaccinated mice challenged with SKOV3 cells. Serum levels of IFN-γ and TGF-β were tested by enzyme
linked immunosorbent assay. The mice were immunized subcutaneously with the inactivated different vaccines and then were challenged by the
SKOV3 cells as described in the section of materials and methods. a Serum IFN-γ level in a various vaccine groups; b Serum TGF-β level in a various
vaccine groups; c. Ovarian cancer tissue TGF-β level in a various vaccine groups. *p <0.05, **p <0.01 and ***p <0.003; refer to the statistically
significant differences as indicated. Data are represented as mean +/− SEM (n = 6)
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The difference was statistically significant (*p < 0.05,
Fig. 4b). In our previous studies, the CD44+CD117+double
positive cell population in the SKOV3 cell line was only
around 3.1–4.2 % [9, 11], and we think that the CD44
+CD117+double positive cell population in ovarian cancer
tiuuses from the CD44+CD117+ CSC immunized mice
was significantly decreased compared with the mice im-
munized with other SKOV3 cell vaccine .
Because the ALDEFLUOR-positive cells have stem
cell characteristics, and may represent CSC popula-
tion [1, 22–24], we further analyzed the ALDH activity in
cells derived from a SKOV3 ovarian tumors detached
from the vaccinated nude mice. In Fig. 5a, FCM analysis
of the xenografted tumor cells showed that ALDEFLUOR-
positive cells in CD117+CD44+CSC vaccine group was ac-
counting for 0.58 % (1.68 % minus 1.10 %), and it was
remarkably decreased in contrast to the SKOV3 cell vac-
cine group for 1.48 % (2.59 % minus 1.11 %, **p < 0.01) or
non-CSC vaccine group for 1.7 % (2.77 % minus 1.07 %,
**p < 0.01) or PBS group for 10.4 % (11.5 % minus 1.10 %,
***p < 0.003) as is shown in Fig. 5b. It is thus evident from
these results that the administration of the CD117+CD44
+CSC vaccine to mice led to disease of the CD44+ CD117
+CSC and ALDH-positive cell populations in ovarian can-
cer tiuuses from immunized mice.
Discussion
EOC still belongs to the most aggressive cancer types
such as high-grade serous ovarian cancer, a devastating
disease with highly recurrence. Surgery and chemother-
apy with taxanes and platinum compounds are very ef-
fective in reducing tumor burden, however, relapses and
Fig. 3 Vaccination with CD117+CD44+CSC vaccine induced NK cell response against SKOV3 ovarian cancer. a FCM analysis results indicate the
cytotoxicity of NK cells in mice immunized with the different vaccines, respectively. The ratio of the effector cells (splenocytes from the immunized
mice) to the target cells (YAC-1cells) was 25:1; b A representative set of data for six mice were used to detect NK cytotoxicity; c and d The analysis
results of qRT-PCR show the expression of perforin and granzyme B in ovarian cancer tissues, respectively. An experiment was repeated twice.
Statistically significant differences are indicated by asterisk for *p < 0.05, **p < 0.01, and ***p < 0.003, respectively
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drug resistance occur frequently. EOC CSCs are thought
to drive the onset of tumor recurrence, distant me-
tastasis, and drug-resistance, which is a significant
clinical problem for the effective treatment of cancer
[2, 3, 25–27]. Thus, targeted treatment of EOC CSC
modalities is eagerly awaited.
To target CSCs for treatment of EOC, we have devel-
oped the SKOV3 CD117+CD44+CSC vaccine to test this
assumption. The data from our courrent study demon-
strated that the CD117+CD44+ CSC vaccine were able to
induce athymic nude mice for generating immune re-
sponses against human EOC SKOV3 cell challenge in
the vaccinated mice. Although the non-CD117+CD44
+CSC and the SKOV3 cell vaccines showed marked effi-
cacy against ovarian cancer as well, this efficacy was ac-
tually more efficient in the mice immunized with the
CD117+CD44+CSC vaccine. The efficacy mechanisms,
we guess, may involve in the elevated serum IFN-γ level,
and the enhanced the cytotoxic activity of NK cells.
IFN-γ was generated by NK cells, while IFN-γ again
reacted on NK cells, which may enhance cell-
mediated cytotoxicity by delivering perforin and gran-
zyme B, and develop central biological role in killing
ovarian cancer cells [20, 28, 29]. Differently, the ma-
lignant tumors secreted the high amounts of TGF-β,
which increased circulating plasma concentration that
is associated with the advanced stage of the tumors
[30–32]. The dysregulation of TGF-β signaling plays a
crucial role in ovarian carcinogenesis and maintaining
CSC properties [33]. In this study, we found that
CD117+CD44+CSC vaccine significantly suppressed
the secretion of TGF-β in ovarian cancer tissues,
which may be one of anti-ovarian cancer mechanisms
by inhibition of ovarian carcinogenesis and regulating
CSC properties.
Because the numbers of CD117+CD44+CSCs and
the ALDEFLUOR-positive cell populations that have
self-renew characteristics, are closely related with the
sensitivity of ovarian cancer to chemotherapy and
radiotherapy as well as patients survival time [34, 35],
we measured the ALDEFLUOR-positive cell changes
in the vaccinated mice to analyze the CSC vaccine ef-
ficient mechanisms. The results demonstrated that the
CD117+CD44+CSC vaccine not only markedly de-
creased the CD117+CD44+CSC population, but also
reduced ALDH-positive cell population in SKOV3
Fig. 4 CD44+CD117+cell population in ovarian cancer tissues in nude mice. 2 × 105 ovarian cancer tissue cell suspension in PBS were labeled with
anti-Human/Mouse CD44 FITC 1:100, and anti-Human CD117 PE 1:20 antibodies for immunofluorescence detection. a FCM analysis shows that
the number of CD44+CD117+double positive cells in CD117+CD44+CSC vaccine group was the lowest among 4 groups, whereas this number was the
highest in PBS group; b Quantitative analysis of CD44+CD117+double positive cells in ovarian cancer tissues from the mice immunized with the
different vaccines. *p <0.05, **p <0.01 and ***p <0.003; refer to the statistically significant differences as indicated
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ovarian cancer tissues from the vaccinated nude mice
compared with the mice vaccinated with other control
vaccines. Consistent with the ALDEFLUOR-positive
cell population, the tumors generated by this popula-
tion occured earlier and grew bigger in PBS vacci-
nated mice than that of mice vaccinated with other
vaccines. These positive consistent data allows us sup-
pose that our developed SKOV3 CD117+CD44+CSC
vaccine induced anti-ovarian cancer efficacy that is
related with the diminution of CD117+CD44+CSC as
well as ALDH-positive cell populations by eliciting ef-
fective immunity in the athymic nude mouse model.
At present time, there are the reports on effective im-
munity against ovarian cancer with xenogeneic poly
antigenic cancer vaccines. These studies have demon-
strated an efficacy of such vaccine with heat shock pro-
tein 70 and tumour dendritic cell fusions that targeted
resistant CSC population or using fusions of dendritic
cells and ovarian cancer-initiating cells that induced the
cytotoxic T lymphocytes against ovarian cancer-initiating
cells [36, 37]. The similar studies such as vaccination with
human embryonic stem cells or mouse embryonic stem
cells demonstrated that this pre-inactivated human or
mouse embryonic stem cell vaccine can induce anti ovar-
ian cancer efficacy in mouse and rat animal models, indi-
cating that the activity of the vaccine is universal, and,
more importantly, it is safe and has a potential for ovarian
cancer [38]. However, to the best of our knowledge, it is
first report that we used the human SKOV3 CD117+CD44
+CSC vaccine to directly immunize the nude mice for
evaluating vaccine efficacy against EOC CSCs. Neverthe-
less, we understand that more studies are fully warranted
to find out the mechanisms for this vaccine before SKOV3
CD117+CD44+CSC-based vaccine is moved into clinical
Fig. 5 CD117+CD44+CSC vaccine decreases ALDH-positive cells in ovarian cancer tissues in mice. Representative FCM analysis of ovarian cancer
tissue cells (2 × 105) using the ALDEFLUOR assay. The sorting gates were established based on DEAB stained controls. DEAB were used to establish
the baseline fluorescence of these cells (R1) and to define the ALDEFLUOR positive cell region (R2). a FCM analysis shows that the number of ALDH
positive cells in CD117+CD44+CSC vaccine group was the lowest among 4 groups, whereas this number was the highest in PBS group; b Quantitative
analysis of ALDH positive cell population in ovarian cancer tissues from the mice immunized with the different vaccines. The number of ALDEFLUOR
positive cell equals to the number in R2 region minus the number in R1 region. **p <0.01 and ***p <0.003; refer to the statistically significant
differences as indicated
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testing. For example, why the SKOV3 CD117+CD44+CSC
vaccine efficacy is better than that of SKOV3 non-CD117
+CD44+CSC and the SKOV3 cell vaccines, and what mol-
ecules elicit a powerful immune responses in this CSC-
based vaccine? Thus, such mechanism requires further
studies.
In summary, this is a preliminary study that is the first
proof for demonstrating the SKOV3 CD117+CD44+CSC
vaccine targets effectively CSCs and inhibits ovarian
tumor growth in xenografted nude mice by eliciting ef-
fective immune resonses against SKOV3 CD117+CD44+
CSCs. This CSC-based vaccine may confer an effective
immunity against ovarian cancer.
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